Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2012 1
2014 1
2015 1
2016 1
2018 2
2019 1
2020 2
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 2 Dyspnea, CTCAE"
Page 1
Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
Montemurro F, Mittica G, Cagnazzo C, Longo V, Berchialla P, Solinas G, Culotta P, Martinello R, Foresto M, Gallizioli S, Calori A, Grasso B, Volpone C, Bertola G, Parola G, Tealdi G, Giuliano PL, Aglietta M, Ballari AM. Montemurro F, et al. JAMA Oncol. 2016 Apr;2(4):445-52. doi: 10.1001/jamaoncol.2015.4720. JAMA Oncol. 2016. PMID: 26720497
IMPORTANCE: Patient perspective on chemotherapy-related adverse effects is being increasingly acknowledged both in experimental clinical trials and in clinical practice. OBJECTIVE: To evaluate a 10-item, paper questionnaire derived from the US National Cancer Instit …
IMPORTANCE: Patient perspective on chemotherapy-related adverse effects is being increasingly acknowledged both in experimental clinical …
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study.
Fabbro M, Jacot W, Jarlier M, Guiu S, D'Hondt V, Pouderoux S, Champoiral P, Janiszewski C, Nicklès I. Fabbro M, et al. Cancer Rep (Hoboken). 2023 Jan;6(1):e1732. doi: 10.1002/cnr2.1732. Epub 2022 Oct 27. Cancer Rep (Hoboken). 2023. PMID: 36302744 Free PMC article.
The overall compliance with self-hypnosis was 68.6% (95% CI: 50.7%-83.2%), meaning that more than two thirds of patients performed at least four sessions of self-hypnosis. According to NCI-CTCAE, Grade 2 nausea and vomiting was observed in 45.7% and 22 …
The overall compliance with self-hypnosis was 68.6% (95% CI: 50.7%-83.2%), meaning that more than two thirds of patients performed at …
No excess harms from sustained-release morphine: a randomised placebo-controlled trial in chronic breathlessness.
Johnson MJ, Sbizzera I, Fairhurst C, Fazekas B, Agar M, Ekstrom M, Currow DC. Johnson MJ, et al. BMJ Support Palliat Care. 2020 Dec;10(4):421-428. doi: 10.1136/bmjspcare-2019-002009. Epub 2019 Nov 12. BMJ Support Palliat Care. 2020. PMID: 31719052 Clinical Trial.
OBJECTIVES: We aimed to identify and evaluate: (1) treatment-emergent adverse events (TEAE (worse or new since baseline)) and the subgroup of severe TEAEs in a placebo-controlled 7-day randomised trial of regular, low-dose, sustained-release oral morphine for chroni …
OBJECTIVES: We aimed to identify and evaluate: (1) treatment-emergent adverse events (TEAE (worse or new since baseline)) and the subgroup o …
IMRT sparing of normal tissues in locoregional treatment of breast cancer.
Caudrelier JM, Meng J, Esche B, Grimard L, Ruddy T, Amjadi K. Caudrelier JM, et al. Radiat Oncol. 2014 Jul 22;9:161. doi: 10.1186/1748-717X-9-161. Radiat Oncol. 2014. PMID: 25052720 Free PMC article. Clinical Trial.
RESULTS: All participants completed the 5-week course of radiation without interruption. Skin erythema was modest and mainly grade 1-2 between the 3rd and the 5th week of radiation treatment. Only 4/30 patients experienced grade 3 skin reactions, mostly seen …
RESULTS: All participants completed the 5-week course of radiation without interruption. Skin erythema was modest and mainly grade 1- …
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Mark M, et al. Cancer Immunol Immunother. 2021 May;70(5):1255-1262. doi: 10.1007/s00262-020-02757-8. Epub 2020 Nov 1. Cancer Immunol Immunother. 2021. PMID: 33130956 Free PMC article. Clinical Trial.
One of these patients (25%) had pre-existing COPD, and three (75%) had baseline dyspnea grade 2-3 related to the tumor. Grade 3 treatment-related AEs (TRAEs) included colonic perforation (grade 5), abdominal pain, and colitis (grade 3 eac …
One of these patients (25%) had pre-existing COPD, and three (75%) had baseline dyspnea grade 2-3 related to the tumor. …
Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.
Kristensen A, Solheim TS, Fløtten Ø, Grønberg BH. Kristensen A, et al. Acta Oncol. 2018 Nov;57(11):1574-1579. doi: 10.1080/0284186X.2018.1492151. Epub 2018 Aug 3. Acta Oncol. 2018. PMID: 30074418
Blood counts were measured weekly in the treatment period. We categorized patients as having severe (CTCAE grade 3-4) or non-severe (grade 0-2) HT during the first chemotherapy cycle. ...There were no significant associations between HT and global qual …
Blood counts were measured weekly in the treatment period. We categorized patients as having severe (CTCAE grade 3-4) or non-s …
Determining the incidence of interstitial pneumonitis and chronic kidney disease following full intensity haemopoetic stem cell transplant conditioned using a forward-planned intensity modulated total body irradiation technique.
Durie E, Nicholson E, Anthias C, Dunne EM, Potter M, Ethell M, Messiou C, Brennan J, Eagle S, Talbot J, Smyth G, Ingram W, Saran F, Mandeville HC. Durie E, et al. Radiother Oncol. 2021 May;158:97-103. doi: 10.1016/j.radonc.2021.02.020. Epub 2021 Feb 23. Radiother Oncol. 2021. PMID: 33636231

Mean doses to the lungs and kidneys were 12-12.5 Gy. Toxicities were defined as per CTCAE v4.0: IP as multilobar infiltrates on CT with symptoms of dyspnoea, and renal dysfunction as an Estimated Glomerular Filtration rate (eGFR) < 60 ml/min/1.73 m(2) for

…
Mean doses to the lungs and kidneys were 12-12.5 Gy. Toxicities were defined as per CTCAE v4.0: IP as multilobar infiltrates on CT wi …
Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.
Owen D, Olivier KR, Mayo CS, Miller RC, Nelson K, Bauer H, Brown PD, Park SS, Ma DJ, Garces YI. Owen D, et al. Radiat Oncol. 2015 Feb 18;10:43. doi: 10.1186/s13014-015-0340-9. Radiat Oncol. 2015. PMID: 25889747 Free PMC article.
Fifty one percent (32/63 patients) experienced acute toxicity, predominantly grade 1 and 2 fatigue. One patient developed acute grade 3 radiation pneumonitis at 75 days. Forty six percent (29/63 patients) developed late effects. Most were grade 1 dy …
Fifty one percent (32/63 patients) experienced acute toxicity, predominantly grade 1 and 2 fatigue. One patient developed acut …
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS, Helman LJ. Fox E, et al. Oncologist. 2012;17(3):321. doi: 10.1634/theoncologist.2010-0265. Epub 2012 Feb 23. Oncologist. 2012. PMID: 22363068 Free PMC article. Clinical Trial.
BACKGROUND: Gemcitabine and docetaxel have a broad spectrum of clinical activity in patients with carcinoma. The Sarcoma Alliance for Research Through Collaboration conducted a phase II trial of gemcitabine in combination with docetaxel in children and adults with r …
BACKGROUND: Gemcitabine and docetaxel have a broad spectrum of clinical activity in patients with carcinoma. The Sarcoma Alliance for …
Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): a phase 2 study.
Pathak N, Garg R, Khurana S, Kumar S, Kumar A, Pushpam D, Khan MA, Mohan A, Pathy S, Yadav M, Prasad CP, Malik PS. Pathak N, et al. J Cancer Res Clin Oncol. 2023 Aug;149(9):6399-6409. doi: 10.1007/s00432-023-04617-1. Epub 2023 Feb 9. J Cancer Res Clin Oncol. 2023. PMID: 36759393 Clinical Trial.
At a median follow-up of 4.8 m (95% CI 3.27-14.9), the median progression-free survival and overall survival were 3.3 months (95% CI 2.36-5.6) and 6.8 months (95% CI 2.47-8.8), respectively. QoL improved for global QoL, role functioning, pain, dyspnea, insomn …
At a median follow-up of 4.8 m (95% CI 3.27-14.9), the median progression-free survival and overall survival were 3.3 months (95% CI 2 …
13 results